Crystal structure of the human NK1 tachykinin receptor.
Jie YinKaren ChapmanLindsay D ClarkZhenhua ShaoDominika M BorekQingping XuJunmei WangDaniel M RosenbaumPublished in: Proceedings of the National Academy of Sciences of the United States of America (2018)
The NK1 tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals. Through activation of NK1R, substance P modulates a wide variety of physiological and disease processes including nociception, inflammation, and depression. Human NK1R (hNK1R) modulators have shown promise in clinical trials for migraine, depression, and emesis. However, the only currently approved drugs targeting hNK1R are inhibitors for chemotherapy-induced nausea and vomiting (CINV). To better understand the molecular basis of ligand recognition and selectivity, we solved the crystal structure of hNK1R bound to the inhibitor L760735, a close analog of the drug aprepitant. Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor. We used our structure as a template for computational docking and molecular-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant. The structure of hNK1R is a valuable tool in the further development of tachykinin receptor modulators for multiple clinical applications.
Keyphrases
- chemotherapy induced
- molecular dynamics simulations
- endothelial cells
- crystal structure
- nk cells
- clinical trial
- small molecule
- binding protein
- depressive symptoms
- induced pluripotent stem cells
- oxidative stress
- pluripotent stem cells
- sleep quality
- molecular docking
- emergency department
- cancer therapy
- deep learning
- protein protein
- artificial intelligence